Foghorn Therapeutics(US:FHTX)2025-11-05 12:02Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly Collaboration Agreement[14] - Net loss for Q3 2025 was $15.8 million, compared to a net loss of $19.1 million in Q3 2024, reflecting improved financial performance[18] - Total operating expenses for Q3 2025 were $26.7 million, down from $31.7 million in Q3 2024[22] - General and administrative expenses were $6.7 million for Q3 2025, down from $7.0 million in Q3 2024, primarily due to lower facilities and IT-related expenses[18] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in FHD-286 and personnel-related expenses[14] - As of September 30, 2025, the company had $180.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028[18] Research and Development - FHD-909 is in a Phase 1 dose escalation trial targeting SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary focus[1] - The Selective CBP degrader program is advancing towards IND readiness in 2026, with promising preclinical data for ER+ breast cancer[7] - The Selective ARID1B degrader program is progressing towards in vivo proof-of-concept in 2026, targeting up to 5% of solid tumors[9] Collaboration - The company is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program[4]